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Abstract
Background: Diabetic type 1 patients are often advised to use dose adjustment guidelines to calculate
their doses of insulin. Conventional methods of measuring patients' adherence are not applicable to these
cases, because insulin doses are not determined in advance. We propose a method and a number of
indicators to measure patients' conformance to these insulin dosing guidelines.
Methods: We used a database of logbooks of type 1 diabetic patients who participated in a summer camp.
Patients used a guideline to calculate the doses of insulin lispro and glargine four times a day, and registered
their injected doses in the database. We implemented the guideline in a computer system to calculate
recommended doses. We then compared injected and recommended doses by using five indicators that
we designed for this purpose: absolute agreement (AA): the two doses are the same; relative agreement
(RA): there is a slight difference between them; extreme disagreement (ED): the administered and
recommended doses are merely opposite; Under-treatment (UT) and over-treatment (OT): the injected
dose is not enough or too high, respectively. We used weighted linear regression model to study the
evolution of these indicators over time.
Results: We analyzed 1656 insulin doses injected by 28 patients during a three weeks camp. Overall
indicator rates were AA = 45%, RA = 30%, ED = 2%, UT = 26% and OT = 30%. The highest rate of absolute
agreement is obtained for insulin glargine (AA = 70%). One patient with alarming behavior (AA = 29%, RA
= 24% and ED = 8%) was detected. The monitoring of these indicators over time revealed a crescendo
curve of adherence rate which fitted well in a weighted linear model (slope = 0.85, significance = 0.002).
This shows an improvement in the quality of therapeutic decision-making of patients during the camp.
Conclusion: Our method allowed the measurement of patients' adherence to their insulin adjustment
guidelines. The indicators that we introduced were capable of providing quantitative data on the quality of
patients' decision-making for the studied population as a whole, for each individual patient, for all
injections, and for each time of injection separately. They can be implemented in monitoring systems to
detect non-adherent patients.
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Background
In some diseases such as diabetes, patients manage their
own therapy. Insulin dependent diabetic patients are
often advised to use dose adjustment guidelines to calcu-
late their doses of insulin for each self-administration.
However, they may follow their guidelines totally, par-
tially, or not at all. The adherence of patients to these
guidelines is very important and can affect their blood
glucose levels.
Methods for measuring patient adherence to drug therapy
include self-reporting [1], patient interviews [2], pill
counting [3], exploration of pharmacy records [4], meas-
uring of active drug metabolites in the blood [5], and
using electronic monitoring devices [6]. However, these
methods are not applicable for the evaluation of patients'
adherence to their insulin adjustment guidelines, because
these guidelines do not determine correct insulin doses in
advance. In fact, dose adjustment guidelines are distinct
from common prescriptions by giving the patients the
role of therapeutic decision-makers.
Diabetes is a major worldwide problem; and non-adher-
ence to antidiabetic therapy and its impacts are well-doc-
umented [7]. Concerning insulin adjustment, the new
technology allows the monitoring of patients through tel-
ecare systems, which store capillary blood glucose (CBG)
and insulin doses [8]. Some systems even allow predicting
of blood glucose based on lifestyle and therapeutic varia-
bles [9]. Although these systems have invaluable role in
providing decision support and improving the quality of
blood glucose control, they do not allow measuring the
patients' conformance to insulin adjustment guidelines.
We present a method as well as a number of indicators
that we developed for analyzing and monitoring of
patients' adherence to their dose adjustment guidelines.
We demonstrate our method in a group of type 1 diabetic
patients who used an insulin dose adjustment guideline
during supervised summer camps. We discuss the results
and explain how our method and especially our indica-
tors can be used in monitoring systems for real-time sur-
veillance.
Methods
Patients
We used a database of logbooks of patients attending
summer camps organized by Aide aux Jeunes Diabétiques
(AJD). The latter is a non-profit organization with a major
role in diabetes education in France. Eligible patients were
those aged between 13 and 17, whose parents accepted
their participation in the study. Non-eligible patients were
those who did not manage their diabetes on their own,
and those with a coexisting disease.
Twenty-eight patients (16 males and 12 females) were
included in the study. They used a guideline to calculate
the doses of their insulin injections four times a day. All
patients had the same diet and the same kind of physical
activity during the camp. Their daily carbohydrate intake
was constant and fixed in advance for each meal by AJD
nutritionists. The camp personnel supervised patients to
assure their good dietary compliance. Physicians regis-
tered patients' CBGs, self-administered insulin doses,
physical activities, and any event on their health status in
an online database (the database is accessible to patients
and their physicians under authentication [10]). The
French Consultative Committee for Protection of Persons
in Biomedical Research (CCPPRB) approved the research
protocol and the guideline. The de-identified patient data-
set is accessible as add-on material to this article. (Addi-
tional file 1). 
The guideline
We used the official AJD guideline, taught to patients dur-
ing summer camp. It consists of two pages of simple rec-
ommendations for the adjustment of insulin dose in a
basal-bolus schema of insulin therapy including one
injection of insulin lispro (or insulin aspart) before each
meal, and one injection of insulin glargine before going to
bed. This guideline was not specific for the kind of insulin,
but for the schema of basal-bolus insulin therapy.
The guideline made use of patient's CBGs, injected doses
of insulin, any advent of hypo- or hyperglycemia, and
physical activity in a rule based algorithm composed of
conditions and actions. It did not take into account carbo-
hydrate intake because it was considered constant for each
meal (breakfast, lunch, snack, and dinner) during the
camp. As an example, to adjust the dose of insulin lispro
before breakfast, the guideline proposed the patient to
consider the CBG results obtained before lunch for two
previous days, CBG measured at the moment of injection,
and any physical activity over the next few hours. The
guideline did not indicate the absolute dose of insulin.
Instead, it provided instructions for the patients to adjust
their own ongoing dose. The guideline is available as add-
on material to this article. (Additional file 1).
Computer methods
We extracted the rules of the guideline manually, and
implemented them in a computer system, written in R
programming language version 2.6.1 [11]. Our system
uses data from patient logbooks to generate a dose adjust-
ment for each insulin injection. It then compares these
computer-generated dose adjustments with patient self-
administered doses (figure 1). The system source code is
available as add-on material to this article.BMC Medical Informatics and Decision Making 2008, 8:55 http://www.biomedcentral.com/1472-6947/8/55
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Designing indicators
In order to be able to formalize and quantify the adher-
ence, we categorized dose adjustments into seven discrete
groups (table 1). We described each dose adjustment by
variations with regard to the ongoing dose. By placing
patient dose adjustments in columns and calculated dose
adjustments in rows of a contingency table, we defined
five indicators for quantifying patient's adherence to the
guideline (figure 2).
System architecture Figure 1
System architecture.BMC Medical Informatics and Decision Making 2008, 8:55 http://www.biomedcentral.com/1472-6947/8/55
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a) Absolute agreement (AA): On-diagonal cell counts,
which correspond to injections for which the patient's
dose adjustment is the same as generated dose adjust-
ment.
b) Under-treatment (UT): Off-diagonal cell counts situ-
ated below the diagonal, which correspond to injections
for which patient's dose adjustment is smaller than gener-
ated dose adjustment. Clinically, this indicator represents
a hypoglycemia avoiding behavior.
c) Over-treatment (OT): Off-diagonal cell counts situated
above the diagonal, which correspond to injections for
which patient's dose adjustment is greater than generated
dose adjustment. Clinically, this indicator represents a
hyperglycemia avoiding behavior.
d) Relative agreement (RA): Off-diagonal cell counts adja-
cent to the diagonal, which correspond to adherent cases,
but with some degree of tolerance.
e) Extreme disagreement (ED): The outermost off-diago-
nal cell counts, which correspond to "potentially danger-
ous" cases. In our study, we defined this area as cell counts
where patient dose adjustment was in an opposite direc-
tion (i.e. increase versus decrease) of generated dose
adjustment.
Statistical methods
We used normal approximation of binomial distribution
to construct confidence intervals (CI) for each indicator.
We used also a weighted linear regression model [12] to
determine the relationship between the time passed in the
camp and each indicator. In the weighted analysis, we
used the value of standard deviation of the indicator as the
weight. Calculations are made by glm( ) function of R pro-
gramming language version 2.6.1.
Results
Patients mean age was 15 (SD = 1) years and their mean
body mass index was 20.3 (SD = 2.8)kg/m2. Mean HbA1C
was 7.8 (SD = 1.2)% at the beginning of the study. Mean
CBG was 130 (SD = 70)mg/dl before breakfast, 170 (SD =
90)mg/dl before lunch, 180 (SD = 90)mg/dl before din-
ner, and 170 (SD = 90)mg/dl at bedtime.
Mean injected daily doses of insulin lispro were 9.5 (SD =
4.4) units before breakfast, 9.4 (SD = 5.3) units before
lunch, and 8.6 (SD = 4.1) units before dinner. Mean
injected daily dose of insulin glargine was 20.7 (SD = 7.2)
units at bedtime.
Physicians made dose adjustments for patients on the first
and the last two days of the camp. On all other days,
patients adjusted themselves their doses of insulin under
the supervision of physicians. Mean percentages of com-
pletion of the online database for dose adjustments before
breakfast, lunch, dinner and at bedtime were respectively
92.6 (SD = 3.8), 90.4 (SD = 5.4), 86.7 (SD = 4.6) and 86.9
(SD = 4.8).
Overall analysis
We analyzed 1656 pairs of dose adjustments (table 2).
Two adjustments "do not change dose" and "decrease
dose by up to 1 unit" were the most common adjustments
in both patient (51% and 15% respectively) and compu-
ter-generated dose adjustments (62% and 20%). While
guideline rules did not allow the dose to be adjusted by
more than 2 units, patients made adjustments by more
than 2 units in 7% of injections.
Overall rates of indicators for all patients and all insulin
types were AA = 45% (CI = 2.3%), RA = 30%(CI = 2.1), ED
= 2%, UT = 26%(CI = 2.3) and OT = 30%(CI = 2.1). As ED
was too close to zero, its confidence interval was not cal-
culated.
Although over-treatment (OT) was more common than
under-treatment (UT), there were less cell counts of
extreme disagreement (ED) in OT area than in UT area (10
and 16 cases respectively). This suggests that extreme dis-
agreement was more likely to be a result of under-treat-
ment, i.e. hypoglycemia-avoiding behavior.
Injection related analysis
We calculated indicators separately for different injections
(table 3). Patients were mostly adherent concerning insu-
lin glargine with a rate of AA = 70% followed by insulin
lispro before breakfast (AA = 38%). By considering RA
cells also as adherent (with some tolerance), insulin lispro
injections before dinner represented the highest level of
adherence (78%).
Table 1: Dose adjustment categories.
Symbol Meaning
< -2 Decrease dose by more than 2 units
-2 Decrease dose by between 1 and 2 units
-1 Decrease dose by between 0 and 1 units
0 Do not change the dose
+1 Increase dose by between 0 and 1 units
+2 Increase dose by between 1 and 2 units
> +2 Increase dose by more than 2 unitsBMC Medical Informatics and Decision Making 2008, 8:55 http://www.biomedcentral.com/1472-6947/8/55
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Patient related analysis
We calculated also the indicators for each patient (table
4). The highest score of adherence to the guideline was
observed in a patient with AA plus RA ratio of 96%. On
the other side, the highest rate of alarming non adherence
-marked by the highest rate of ED indicator- was detected
in a patient with an ED rate of 8%.
Time related analysis
We analyzed the evolution of patients' therapeutic deci-
sions over time by tracing the indicators of each day sepa-
rately (figure 3). The AA plus RA curve, which was more
interesting for clinicians than AA or RA alone, showed an
increasing trend during the camp. The ED curve showed
fluctuations apparently due to different weekend activities
and feasts (non-adherence to the guideline increased dur-
ing festivities). OT and UT curves showed that over-treat-
ment was more common than under-treatment, almost
all time.
We fitted a weighted generalized linear model to examine
the evolution of each indicator. The model fitted well (sig-
nificance = 0.002) for the AA plus RA curve, but not for
other indicators. It showed that the overall agreement pro-
gressed during the camp, and the rates of over- and under-
treatments decreased smoothly. The extreme disagree-
ment indicator, however, did not show a sensible change.
Indicators of adherence Figure 2
Indicators of adherence.BMC Medical Informatics and Decision Making 2008, 8:55 http://www.biomedcentral.com/1472-6947/8/55
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Discussion
We presented a method for measuring and analyzing
patients' adherence to an insulin dose adjustment guide-
line. A computer system deployed the guideline, and gen-
erated dose adjustments for each insulin injection. The
system compared these dose adjustments with patient-cal-
culated dose adjustments, using contingency tables and
related indicators. We traced the fluctuations of indicators
over time, and showed their significance by use of a
weighted linear regression model.
By using indicators for measuring patients' adherence to
guidelines, this study extends the method comparing
insulin dose adjustments to computer-based insulin dose
adjustment algorithms [13]. The implementation of insu-
lin adjustment algorithms in a computer program and
comparing generated results with patient-calculated
results is already documented in another study, but with-
out the use of indicators. Its authors reported an overall
rate of adherence to the guideline of 89%. This adherence
rate is comparable to the AA plus RA ratio (75%) obtained
in our study. They did not deal with day-to-day changes in
the adherence, or with particular types of patient behav-
ior, such as under- or over-treatment [14].
We used a locked database in retrospective "offline" set-
tings, but the same method with no change is actually
applicable for an online database to monitor patients'
adherence in real-time.
Three indicators, namely AA, OT, and UT, are based on
statistically known concepts of on- and off-diagonal val-
ues of contingency tables. We designed two more indica-
tors of RA and ED, which overlap with other indicators,
for their clinical interest. The width of the zones defining
these indicators on the contingency table depends on how
precise the users of the method want to define their dis-
crete categories. For example, if categories of dose adjust-
ment were defined in two-unit intervals rather than one-
unit intervals, the zone of relative agreement would be
absorbed by that of absolute agreement (in this case, the
categories would be < -2, -2, 0, +2, > +2, and the contin-
gency table would have 25 cells instead of 49).
In our study, patient-calculated dose adjustments were in
"absolute agreement" with those generated by the compu-
ter in less than half of injections (AA = 45%). We intro-
duced the notion of "relative agreement" to detect those
injections (RA = 30%) which are not strictly the same
doses as calculated by the computer, but can be consid-
ered acceptable with a degree of tolerance of one unit. A
similar strategy is used in the analysis of glucometer per-
Table 2: Patients' versus computer-generated dose adjustments.
PATIENT DOSE ADJUSTMENTS
< -2 -2 -1 0 1 2 > +2 Total
GUIDELINE DOSE ADJUSTMENTS < -2 0 103000 4
-2 38 4 4 9 4 6 0 7 4
-1 13 37 75 125 49 23 4 326
0 31 69 143 609 101 51 28 1032
1 12 14 23 49 46 29 15 188
2 22 3 1 8 5 2 0 3 2
> +2 0 000000 0
Total 61 131 248 853 205 111 47 1656
Table 3: Indicator rates for each insulin injection.
I n j e c t i o n A AR AE DU TO TN
Lispro before breakfast 38 35 2 28 34 426
Lispro before lunch 37 36 2 33 30 419
Lispro before dinner 33 45 1 26 41 391
Glargine before sleep 70 6 2 15 15 420
N: number of injections.BMC Medical Informatics and Decision Making 2008, 8:55 http://www.biomedcentral.com/1472-6947/8/55
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formances in form of the well-known Error Grid Analysis
[9,15].
While measuring the impact of educational camps, it is
especially interesting to know if there is an improvement
in patients' adherence during the camp. In our study, this
is confirmed by the crescendo curve of cumulative AA and
RA indicators during the camp, which is demonstrated by
a well-fitted linear model. However, for other indicators
we could not fit a statistically significant model, which
means that their predictive value for the studied popula-
tion was limited.
The detection of alarming situations is of paramount
importance in monitoring of patient's adherence. The
extreme disagreement (ED) indicator is designed to satisfy
this need. Although its overall trend is shown to be stable
by the regression line, its peaks may necessitate interven-
tion in a real-time monitoring system (figure 3).
Two indicators, UT and OT, explain at least partly what
patients do when they do not follow the guideline, and
why. For example, the frequency of OT is particularly high
for a patient (table 4). This implies that this patient tends
to try to avoid hyperglycemia by injecting a greater dose of
insulin than what is recommended by the guideline. In a
monitoring system using our indicators, this patient can
be easily detected.
A limitation of our study is that the significance of our
indicators depends on the number of observations. There-
fore, we need an initial period of a few days before being
able to monitor a patient's behavior. Another limitation is
the guideline itself. In fact, in 2006, AJD used the same
guideline for both patients under insulin lispro and
patients under insulin aspart. As our study was non-inter-
ventional, we used the guideline which was actually
taught to the studied population during 2006. However,
the study on this guideline showed some of its shortcom-
ings, and helped developing a new version of the guide-
line the following years.
Our proposed method and indicators are not specific to
insulin self-administration. They can be applied in any
other disease where patients decide for their dose of ther-
apy, such as asthma or migraine headache.
Conclusion
Our method allowed the analysis and monitoring of
patients' adherence to an insulin adjustment guideline.
The indicators were capable of providing quantitative data
on the adherence of patients to the guideline not only for
the studied population as a whole, but also for each indi-
vidual patient. We are currently implementing these indi-
cators in a telemedicine project, supported by the French
Table 4: Indicator rates for individual patients.
Patient number AA RA ED UT OT N
1 29 24 8 35 36 66
2 47 26 3 28 26 58
3 57 26 0 10 33 42
4 54 29 0 29 17 63
5 29 31 2 27 45 49
6 61 35 0 18 21 66
7 38 24 2 40 22 50
8 45 40 0 21 34 58
9 41 41 0 41 18 68
10 38 38 5 29 33 58
11 44 19 2 24 32 63
12 42 19 3 22 36 67
13 56 27 0 25 18 55
14 52 21 2 24 24 58
15 52 12 2 21 27 56
16 50 34 1 24 26 68
17 41 35 2 33 25 51
18 50 27 2 20 30 56
19 45 36 0 23 32 53
20 39 34 0 37 24 62
21 46 29 2 25 29 65
22 33 29 3 18 48 66
23 62 27 0 14 23 64
24 40 38 0 27 33 52
25 37 33 0 37 27 52
26 31 34 2 17 52 64
27 48 34 0 23 28 64
28 44 37 3 26 31 62
All 45 30 2 26 30 1656
N: number of injections.BMC Medical Informatics and Decision Making 2008, 8:55 http://www.biomedcentral.com/1472-6947/8/55
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National Authority for Health (FNAH), which aimed at
monitoring young diabetic patients in real-time, and at
alerting their non-adherent behavior to their physicians.
Abbreviations
CBG: capillary blood glucose; FNAH: French National
Authority for Health; AJD: Aide aux Jeunes Diabétique;
SD: Standard deviation; CI: Confidence interval; AA:
Absolute agreement; RA: Relative agreement; OT: Over
treatment; UT: Under treatment; ED: Extreme disagree-
ment.
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